Vical Reports Issuance Of US Patent

Vical Incorporated (Vical) has reported the issuance of US Patent No. 7,582,613 covering Vaxfectin-formulated DNA vaccines for influenza.

The company said that the patent provides broad coverage for any circulating or potential influenza viruses, including both seasonal and pandemic strains.

The company is currently developing Vaxfectin-formulated DNA vaccines for both H5N1 avian-origin and H1N1 swine-origin pandemic influenza.

Reportedly, the new ‘613 patent broadly covers DNA vaccines formulated with any cationic lipid/co-lipid adjuvant formulations from the class including Vaxfectin, and targeting any strain of influenza.

The company said that it has additional issued patents covering the composition and use of the Vaxfectin adjuvant.